JP2016512214A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512214A5
JP2016512214A5 JP2015562176A JP2015562176A JP2016512214A5 JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5 JP 2015562176 A JP2015562176 A JP 2015562176A JP 2015562176 A JP2015562176 A JP 2015562176A JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
epitope
amino acid
tfpi
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562176A
Other languages
English (en)
Japanese (ja)
Other versions
JP6586016B2 (ja
JP2016512214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055055 external-priority patent/WO2014140240A1/en
Publication of JP2016512214A publication Critical patent/JP2016512214A/ja
Publication of JP2016512214A5 publication Critical patent/JP2016512214A5/ja
Application granted granted Critical
Publication of JP6586016B2 publication Critical patent/JP6586016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562176A 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体 Active JP6586016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361789274P 2013-03-15 2013-03-15
US61/789,274 2013-03-15
EP13159515 2013-03-15
EP13159515.9 2013-03-15
PCT/EP2014/055055 WO2014140240A1 (en) 2013-03-15 2014-03-14 Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

Publications (3)

Publication Number Publication Date
JP2016512214A JP2016512214A (ja) 2016-04-25
JP2016512214A5 true JP2016512214A5 (OSRAM) 2017-04-20
JP6586016B2 JP6586016B2 (ja) 2019-10-02

Family

ID=47877935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562176A Active JP6586016B2 (ja) 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体

Country Status (6)

Country Link
US (2) US9896513B2 (OSRAM)
EP (1) EP2970499B1 (OSRAM)
JP (1) JP6586016B2 (OSRAM)
CN (1) CN105209497B (OSRAM)
ES (1) ES2926773T3 (OSRAM)
WO (1) WO2014140240A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745317C (en) 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
EP3022228B1 (en) * 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CR20160319A (es) * 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
DK3277321T3 (da) 2015-04-01 2024-09-02 Anaptysbio Inc Antistoffer, der er rettet mod T-celle-immunglobulin og mucin-protein 3 (TIM-3)
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US10794896B2 (en) * 2016-01-29 2020-10-06 Sony Corporation Blood coagulation system examination module, blood coagulation system examination system, blood coagulation system examination method, and determination method of parameter for blood coagulation system examination module
MA46113A (fr) * 2016-11-01 2019-07-10 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
TWI841209B (zh) 2017-01-09 2024-05-01 美商提薩羅有限公司 用抗tim-3抗體治療癌症之方法
US20210395391A1 (en) 2018-10-11 2021-12-23 Pfizer Inc. Dosage Regimen for TFPI Antagonists
EP3876910A4 (en) * 2018-11-07 2022-08-03 Baudax Bio, Inc. METHOD OF TREATMENT OF SUBJECTS WITH PLATELET DYSFUNCTION WITH IV MELOXICAM
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN112390884B (zh) * 2019-04-09 2022-07-08 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0893439B1 (en) 1989-04-19 2005-07-27 Enzon, Inc. A process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ ノルディスク アクティーゼルスカブ ラミニン−5γ2結合性ペプチド、その関連組成物およびその使用
EP1893239A2 (en) 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of growth hormone
CA2745317C (en) 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
JP5791512B2 (ja) 2008-12-22 2015-10-07 ノヴォ ノルディスク アー/エス 組織因子経路阻害因子(tfpi)に対する抗体
EP2588499B1 (en) 2010-06-30 2020-04-08 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
EP2694544B1 (en) * 2011-04-01 2019-01-23 Bayer HealthCare LLC Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Similar Documents

Publication Publication Date Title
JP2016512214A5 (OSRAM)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
AR075798A1 (es) Proteinas de union a il-17 (interleuquina 17)
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
JP2017529097A5 (OSRAM)
HRP20150439T1 (hr) Protutijela za humani angiopoietin 2
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
JP2017113019A5 (OSRAM)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
IL299282B1 (en) Enhanced variable complexes of immunoglobulins
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
JP2011182794A5 (OSRAM)
JP2017508475A5 (OSRAM)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
JP2013520996A5 (OSRAM)